Today Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Tetraphase Pharmaceuticals ( TTPH) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Tetraphase Pharmaceuticals as such a stock due to the following factors:

  • TTPH has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.4 million.
  • TTPH has traded 5,591 shares today.
  • TTPH is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TTPH with the Ticky from Trade-Ideas. See the FREE profile for TTPH NOW at Trade-Ideas

More details on TTPH:

Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Currently there are 6 analysts that rate Tetraphase Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Tetraphase Pharmaceuticals has been 294,200 shares per day over the past 30 days. Tetraphase has a market cap of $458.6 million and is part of the health care sector and drugs industry. Shares are up 31.1% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Analysis:

TheStreet Quant Ratings rates Tetraphase Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow.

If you liked this article you might like

5 Stocks to Trade for Big Breakout Gains

Monsanto, Amazon and Apple: Doug Kass' Views

Tetraphase Pharmaceuticals (TTPH) Weak On High Volume Today

Tetraphase Pharmaceuticals (TTPH): Today's Weak On High Volume Stock

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass